Popular on EntSun
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 274
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 244
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick - 187
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide - 172
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform - 171
- "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society - 150
- Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion - 136
- VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 135
- Phillip E. Walker's Hollywood Actor Jobs Dec. 10-20, 2025 PRE-TOUR Launches with SweetestVacation.com at CulverCityFilmFestival.com & Closes in the IE - 129
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor - 117
Similar on EntSun
- Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
- RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
- MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
- Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
- How Democrats Made Healthcare More Expensive in 2026
- Inkdnylon Launches Bilingual Ask Inkdnylon Platform
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe USA - English USA - English
EntSun News/10892356
SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
For further information on this analysis, please visit: http://frost.ly/62g
"Advances in RNA stability, manufacturing, chemical modification, and targeted delivery systems have led to the commercial translation of RNA therapeutics," said Ruplekha Choudhurie, TechVision Industry Analyst at Frost & Sullivan. "RNAs are relatively easy to manufacture, cost-effective, and can act on undruggable targets. As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
More on EntSun News
- Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
- Waarom brand mentions in ChatGPT steeds belangrijker worden
- Destination: Scientology Shines with Team Spirit in Columbus at 2025 Dotcomm Awards
- Grandview Art & Auctions Brings the Hard Rock Hotel Art Legacy to Collectors Worldwide
- Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
Choudhurie added: "RNAs have certain advantages over deoxyribonucleic acid (DNA) and small molecule drugs, such as eliminating the risk of genomic integration, being relatively cost-effective, and having rapid development and production. Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants. Specifically, for the development of vaccines for COVID-19 and other emerging infectious disease outbreaks, mRNA vaccines have an advantage over other types of vaccines as they can be rapidly developed and amenable to modifications to target evolving viral variants."
The advantages of RNA therapeutics over conventional small molecule drugs and other biological drugs present immense growth opportunities for market players, including:
- Formulation and delivery of RNA therapeutics: Lipid-nanoparticles were used for delivery formulation in the previously approved RNA therapeutics, and similar (RNA-LNPs) formulations have been considered standard. Rapid formulation and delivery advances will improve the future of RNA delivery and help overcome the intrinsic stability issues of RNA.
- Stability of mRNA vaccines and RNA therapeutics at ambient temperature: Novel formulations that improve mRNA stability at ambient temperatures would facilitate the worldwide application of mRNA vaccines more rapidly and at a much lower cost. This will benefit mRNA vaccines and the entire RNA therapeutics field in general.
- mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics. Due to this, many stakeholders are investing heavily in mRNA vaccines.
Global RNA Therapeutics: Technology Growth Opportunities is the latest addition to Frost & Sullivan's TechVision research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
More on EntSun News
- At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
- Showtime Goin' Native Comedian Marc Yaffee Comes To Wasila Friday January 30
- Attention ALL MEDIA COMPANIES: You are going to LOVE the ADVERTISING REVENUES from this very special kind of VALENTINE'S DAY PROMOTION!
- Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
- TAP Announces Open Auditions for 2026 Season
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Global RNA Therapeutics: Technology Growth Opportunities
DA00
Contact:
Mariana Fernandez
Corporate Communications
E: [email protected]
http://ww2.frost.com
SOURCE Frost & Sullivan
Related Links
www.frost.com
Filed Under: Business
0 Comments
Latest on EntSun News
- Creators' Rights Movement Advances Copyright Rights and Generational Ownership
- Canyons & Chefs Announces Revamped Homepage
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
- Bay Street Yard to host 'Charitable Pour' bourbon pairing dinner Jan. 21
- Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
- MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
- The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
- Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
- Anne Seidman: Within the Lines
- How Democrats Made Healthcare More Expensive in 2026
- Inkdnylon Launches Bilingual Ask Inkdnylon Platform
- Proving Humanity One Click at a Time: Joseph Neibich Nybyk on Turning Captchas into Spiritual Quests
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
- ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
- 11 Wins, Limitless Impact: 2025 Viddy Awards Honor Scientology Media Productions
- Live Comedy Returns To Rogue River On January 23
- Marc Yaffee Comes To Stubby's Cool January 17
- 13th Annual Baton Rouge Mardi Gras Festival
- Introducing "Like A Virgin" — A New Bridal Brand for the Modern, Untraditional Bride
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle